Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E13.12 EPS (ttm)8.80 Insider Own0.50% Shs Outstand1.47B Perf Week-4.96%
Market Cap169.68B Forward P/E10.46 EPS next Y11.04 Insider Trans-18.16% Shs Float1.46B Perf Month3.21%
Income14.21B PEG0.99 EPS next Q2.64 Inst Own85.80% Short Float2.45% Perf Quarter15.08%
Sales27.49B P/S6.17 EPS this Y306.10% Inst Trans-1.77% Short Ratio3.25 Perf Half Y23.55%
Book/sh11.55 P/B10.00 EPS next Y2.43% ROA42.70% Target Price122.00 Perf Year39.71%
Cash/sh7.69 P/C15.02 EPS next 5Y13.30% ROE91.30% 52W Range82.33 - 123.37 Perf YTD22.93%
Dividend1.72 P/FCF10.33 EPS past 5Y39.10% ROI44.80% 52W High-5.20% Beta0.70
Dividend %1.49% Quick Ratio2.40 Sales past 5Y28.80% Gross Margin86.00% 52W Low42.06% ATR2.12
Employees7000 Current Ratio2.70 Sales Q/Q51.90% Oper. Margin64.00% RSI (14)52.50 Volatility1.92% 1.64%
OptionableYes Debt/Eq0.72 EPS Q/Q107.50% Profit Margin51.70% Rel Volume0.93 Prev Close115.46
ShortableYes LT Debt/Eq0.69 EarningsJul 22 AMC Payout4.60% Avg Volume11.02M Price116.96
Recom2.00 SMA20-0.63% SMA505.50% SMA20012.01% Volume4,886,392 Change1.30%
Jun-23-15Reiterated Argus Buy $130 → $150
May-01-15Reiterated RBC Capital Mkts Outperform $118 → $120
May-01-15Reiterated Piper Jaffray Overweight $116 → $120
Feb-04-15Reiterated RBC Capital Mkts Outperform $125 → $118
Dec-23-14Reiterated Deutsche Bank Buy $142 → $125
Dec-09-14Reiterated Argus Buy $110 → $130
Oct-29-14Reiterated RBC Capital Mkts Outperform $115 → $125
Oct-13-14Reiterated FBR Capital Outperform $125 → $130
Sep-25-14Reiterated Needham Buy $95 → $120
Aug-22-14Reiterated RBC Capital Mkts Outperform $102 → $115
Aug-15-14Initiated FBR Capital Outperform $125
Aug-11-14Reiterated Argus Buy $90 → $110
Jul-28-14Reiterated Maxim Group Buy $112 → $127
Jul-24-14Reiterated RBC Capital Mkts Outperform $96 → $102
Apr-28-14Reiterated Maxim Group Buy $101 → $112
Feb-21-14Reiterated Barclays Overweight $90 → $95
Feb-10-14Reiterated Argus Buy $84 → $90
Feb-05-14Reiterated RBC Capital Mkts Outperform $90 → $96
Feb-05-14Reiterated Needham Buy $85 → $95
Feb-05-14Reiterated Maxim Group Buy $98 → $101
Jun-30-15 10:43AM  Is Celgene's Juno Deal a Boon or a Boondoggle? at Barrons.com
10:00AM  Juno-Celgene in Immunotherapy Deal, Initial Deal Value $1B - Analyst Blog
Jun-29-15 03:40PM  Gilead Sciences (GILD) Stock Declines on Lawsuit Seeking Access to Clinical Trial Data at TheStreet
03:04PM  The Overlooked Reason Why I Think Gilead Sciences Stock Remains Undervalued at Motley Fool
02:46PM  Health groups sue FDA for Gilead hepatitis C drug trial data Reuters
11:24AM  FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data at The Wall Street Journal
09:05AM  3 Stocks to Buy if Biotech Crashes at Motley Fool
Jun-27-15 06:32PM  WEEKEND VIDEO: Market Positives and Negatives
06:02PM  Biotech Short-Sellers Prefer Amgen To Gilead Sciences
Jun-26-15 06:35PM  BioMarin DMD Drug Drisapersen Validated for EU Review - Analyst Blog
05:45PM  A new look at AIDS data, with an assist from Gilead at bizjournals.com
05:28PM  Acquisitions May Fuel Gilead Sciences' Winning Ways at Investor's Business Daily
05:02PM  Can Cambrex Keep Profits Healthy On Gilead Pact? at Investor's Business Daily
04:45PM  Eli Lilly Wins Alimta Patent Lawsuit in the UK, Shares Up - Analyst Blog
12:50PM  Gilead Sciences: New Scripts for Harvoni/Sovaldi Decelerating at Barrons.com
Jun-25-15 07:08PM  Biz Break: Tesla gets boost from loyal customers at San Jose Mercury News
07:05PM  Alan Fournier Sells Stake in Gilead Sciences
12:43PM  Gilead's Powerful Bull Run Is Showing Signs of Exhaustion at TheStreet
11:50AM  The six best sectors for 2015s second half at MarketWatch
Jun-24-15 08:41PM  Could This Patent Decision Be Trouble for Gilead? at Investopedia
03:46PM  Stocks Held Hostage by a Stubborn Bond Market at Barrons.com
03:38PM  The 50 Most Innovative Firms On The Stock Market In One Fund at Forbes
02:40PM  Vanda Pharmaceuticals' Schizophrenia Drug Shows Success - Analyst Blog
01:35PM  Matthew Tewksbury Unlocked Joel Greenblatts Magic Formula at Insider Monkey
01:35PM  [$$] Gilead Can Gallop Higher: Biotech Ace 'Breaking Out' at Barrons.com
08:44AM  Biotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog
08:41AM  Macrocure (MCUR) Falls: Stock Goes Down 10% - Tale of the Tape
08:02AM  Large-Cap Mutual Funds' Sweet Spot: Growth And Core at Investor's Business Daily
Jun-23-15 05:18PM  Gilead Leads 4 Top Stocks In Or Near Top Of Buy Areas at Investor's Business Daily
03:45PM  Isis Pharmaceuticals Up on Spinal Muscular Atrophy Data - Analyst Blog
10:48AM  Obamacare ruling, Taylor Swift's Apple saga, and Amazon still selling Confederate flag
Jun-22-15 07:30PM  Are These 3 Biotech Stocks Dirt Cheap? at Investopedia
03:15PM  Gilead Patent for Sovaldi Rejected in China, Shares Down - Analyst Blog
01:56PM  Where Can Mega-Drug Stock Gilead Sciences Go Now? at Investor's Business Daily
11:50AM  Epizyme Lead Candidate Effective in Ongoing Cancer Study - Analyst Blog
09:52AM  Billionaire Cooperman Isnt Gambling With These Stocks Anymore at Insider Monkey
Jun-21-15 03:19PM  Weekend Market VIDEO: Apple, Stocks to Watch, and Biotech
Jun-20-15 02:38PM  China Rejects Gilead's Sovaldi Patent Application
Jun-19-15 10:51PM  High cost of hepatitis drug reflects a broken pricing system at Los Angeles Times
07:42PM  Better Dividend Stock: Amgen or Gilead Sciences? at Investopedia
03:19PM  Biotech to break out, buy these names: Analyst at CNBC
01:41PM  Biotechs about to break out: Pro
01:38PM  Gilead Patent for its Sovaldi Hep C Drug is Rejected by Chinese Authorities at The Wall Street Journal
01:18PM  Gilead Sciences: New Harvoni Prescriptions Decelerate at Barrons.com
12:42PM  These Fortune 500 companies leapfrogged the rest at Fortune
11:45AM  Report: Big Pharma is getting more worried about drug price pushback at bizjournals.com
10:23AM  Gilead Sciences (GILD) Stock Declines as China Rejects Sovaldi Patent Application at TheStreet
07:50AM  Early movers: HSY, RHT, SWHC, STT, CAG & more at CNBC
04:24AM  China rejects patent linked to Gilead hepatitis C drug Reuters
12:00AM  China rejects Gilead hepatitis C drug patent -advocacy group
Jun-18-15 05:40PM  Biotech's big boost
05:34PM  What's driving hedge funds?
04:30PM  Eli Lilly Reports Data on Migraine Drug; Inks Oncology Deals - Analyst Blog
04:25PM  Synergy Pharmaceuticals Soars on Constipation Drug Data - Analyst Blog
02:54PM  Biotech ETF Hits Record: How Much Higher Can It Go? at Barrons.com
09:00AM  How to get More Momentum out of a Nasdaq ETF
08:39AM  Lion Biotechnologies (LBIO) Falls: Stock Goes Down 9.1% - Tale of the Tape
Jun-17-15 02:30PM  Genomic Health Liquid Biopsy Test Fit for Bladder Cancer - Analyst Blog
Jun-16-15 12:59PM  Halftime's hottest trades today: GILD, TWTR, NFLX, & GOOG...
12:04PM  10 Stock Picks from Top Fund Managers at Barrons.com
11:37AM  These five Fortune 500 companies had the fastest revenue growth at Fortune
09:20AM  Where to put money in a "stuck" market
08:02AM  Top Health Care Funds: Can Outperformance Continue? at Investor's Business Daily
Jun-15-15 11:46PM  Why Insider Selling Is a Bad Reason to Sell Gilead at Investopedia
04:45PM  Agios Reports New Data on Hematologic Malignancy Drugs - Analyst Blog
04:35PM  Celgene Presents Positive SPRINT Study Data on Revlimid - Analyst Blog
04:30PM  Alnylam Reveals Positive Initial Data on RNAi Drug ALN-CC5 - Analyst Blog
04:25PM  ARIAD (ARIA) Presents Favorable Long-Term Data on Iclusig - Analyst Blog
02:54PM  Go short, go big, or go away?
02:13PM  Biotech's Rally Has Long-Term Legs, Asserts S&P Capital IQ Director at TheStreet
Jun-14-15 02:38PM  Biotech Gets a Reality Check at The Wall Street Journal
Jun-12-15 03:08PM  How to Trade 5 of the Market's Most Active Stocks -- Buy, Hold or Sell? at TheStreet
02:20PM  Isis Pharmaceuticals Up on Positive Data on ISIS-SMNRx - Analyst Blog
01:43PM  Why Gilead May be the Strongest Company in the World
12:54PM  Gilead Sciences: A Prescription PickupFinally at Barrons.com
10:58AM  Gilead's Stock Chart Warns of Pullback Ahead at TheStreet
10:21AM  Heres what CEOs said about the economy this week
10:10AM  Stock Market News for June 12, 2015 - Market News
07:57AM  Big Biotech Stocks See Declining Short Interest
Jun-11-15 06:57PM  Cramer: Massive biotech moves that make sense at CNBC
04:01PM  Prisoners Sue Massachusetts for Withholding Hepatitis C Drugs at The Wall Street Journal
02:57PM  No One Knows Why Gilead is Flying at Barrons.com
02:00PM  Gilead's President Spoke At Goldman Sachs' Global Healthcare Conference This Week: Here Are The Highlights
Jun-10-15 09:09PM  Gilead Sciences' Under-the-Radar Growth Machine at Investopedia
08:15PM  The End of Aids?Are We Any Closer? at Fox Business
04:50PM  Roche's Actemra Gets Breakthrough Therapy Designation - Analyst Blog
01:46PM  Speed Plus Endurance Horses: Apple, Gilead, Facebook, Amazon And Alibaba at Forbes
12:06PM  7 Things to Know About Gilead Sciences - Stocks in the News
12:04PM  Chinese Stocks Merit a Cautious Approach Now, Says Janney Strategist at TheStreet
11:24AM  Gilead Sciences: Back in the Driver's Seat at Barrons.com
10:06AM  How to Trade the Stocks of Four Giants in the Health Care Industry at TheStreet
08:15AM  Pro sticks with top picks
07:55AM  Short Sellers Lose Some Conviction Against Big Biotech at 24/7 Wall St.
Jun-09-15 02:07PM  Transports flashing warning, but won't drop: Pro
10:00AM  Roche to Develop Diagnostic Test for Cardiovascular Disease - Analyst Blog
09:40AM  Jazz Pharmaceuticals' Sleep Disorder Drug Enters Phase III - Analyst Blog
08:00AM  Two Big Biotech ETFs
Jun-08-15 06:13PM  Eli Lilly (LLY) Presents Encouraging Data on Diabetes Drugs - Analyst Blog
05:11PM  Gilead CEO's $17 Million Planned Stock Sale at Barrons.com
05:00PM  Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 9 Business Wire
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company, Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carter Paul RutherfordEVP Commercial OpsJun 18Option Exercise26.9910,000269,90057,632Jun 22 04:17 PM
Carter Paul RutherfordEVP Commercial OpsJun 18Sale120.0010,0001,200,02547,632Jun 22 04:17 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 15Option Exercise21.5870,0001,510,250235,168Jun 17 07:25 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 15Sale117.6770,0008,237,002165,168Jun 17 07:25 PM
MILLIGAN JOHN FPresident and COOJun 08Option Exercise14.50100,0001,450,2501,129,108Jun 10 01:03 PM
MILLIGAN JOHN FPresident and COOJun 08Sale114.05100,00011,405,4131,029,108Jun 10 01:03 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise34.713,000104,12050,632Jun 03 06:07 PM
MARTIN JOHN CChairman and CEOJun 01Option Exercise14.50150,0002,175,3754,405,876Jun 03 06:07 PM
Alton Gregg HEVP, Corp & Med AffairsJun 01Option Exercise23.7115,000355,647158,422Jun 03 06:07 PM
MARTIN JOHN CChairman and CEOJun 01Sale113.95150,00017,092,3444,255,876Jun 03 06:07 PM
Alton Gregg HEVP, Corp & Med AffairsJun 01Sale113.6417,0001,931,891141,422Jun 03 06:07 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale113.093,000339,27847,632Jun 03 06:07 PM
Carter Paul RutherfordEVP Commercial OpsMay 15Option Exercise67.786,000406,68753,632May 19 07:24 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 15Option Exercise21.3470,0001,493,550235,168May 19 07:25 PM
Alton Gregg HEVP, Corp & Med AffairsMay 15Option Exercise19.2025,000479,947168,422May 19 07:25 PM
Carter Paul RutherfordEVP Commercial OpsMay 15Sale110.006,000660,02047,632May 19 07:24 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 15Sale109.4570,0007,661,533165,168May 19 07:25 PM
Alton Gregg HEVP, Corp & Med AffairsMay 15Sale110.0125,0002,750,210143,422May 19 07:25 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000050,439May 12 06:02 PM
MILLIGAN JOHN FPresident and COOMay 07Option Exercise14.50100,0001,450,2501,129,108May 11 08:24 PM
MILLIGAN JOHN FPresident and COOMay 07Sale101.00100,00010,100,1621,029,108May 11 08:24 PM
Whitley Richard JamesDirectorMay 05Option Exercise19.6321,720426,36437,361May 07 05:14 PM
Carter Paul RutherfordEVP Commercial OpsMay 01Option Exercise80.652,000161,30047,439May 05 04:23 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise14.50150,0002,175,3754,405,876May 05 05:47 PM
Washington Robin LEVP, CFOMay 01Option Exercise29.7016,842500,13044,566May 05 07:38 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise19.0910,000190,850155,422May 05 07:38 PM
Washington Robin LEVP, CFOMay 01Sale105.0616,8421,769,40527,724May 05 07:38 PM
MARTIN JOHN CChairman and CEOMay 01Sale104.95150,00015,742,4914,255,876May 05 05:47 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale104.0712,0001,248,871143,422May 05 07:38 PM
Carter Paul RutherfordEVP Commercial OpsMay 01Sale103.182,000206,36545,439May 05 04:23 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 15Option Exercise20.7470,0001,451,800235,168Apr 17 02:23 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 15Sale103.8470,0007,268,627165,168Apr 17 02:23 PM
Alton Gregg HEVP, Corp & Med AffairsApr 08Option Exercise19.095,00095,425150,422Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise80.651,00080,65046,439Apr 09 04:40 PM
Alton Gregg HEVP, Corp & Med AffairsApr 08Sale100.005,000500,000145,422Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale100.001,000100,00045,439Apr 09 04:40 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise14.50150,0002,175,3754,405,876Apr 03 05:24 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise80.651,00080,65046,439Apr 03 05:24 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise19.095,00095,425152,422Apr 03 05:24 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale98.041,00098,04445,439Apr 03 05:24 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale96.537,000675,715145,422Apr 03 05:24 PM
MARTIN JOHN CChairman and CEOApr 01Sale96.74150,00014,511,4634,255,876Apr 03 05:24 PM
Whitley Richard JamesDirectorMar 02Option Exercise26.995,000134,95020,641Mar 03 04:12 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Option Exercise19.0910,000190,850159,422Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Option Exercise14.50150,0002,175,3754,405,876Mar 04 07:48 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Option Exercise80.652,000161,30047,439Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Sale103.51150,00015,526,2454,255,876Mar 04 07:48 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Sale103.6312,0001,243,615147,422Mar 04 07:49 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Sale104.182,000208,36445,439Mar 04 07:49 PM
Whitley Richard JamesDirectorMar 02Sale103.435,000517,13615,641Mar 03 04:12 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Option Exercise16.4070,0001,147,650235,168Feb 19 06:42 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Sale103.0170,0007,210,740165,168Feb 19 06:42 PM
WOLD OLSEN PERDirectorFeb 06Buy99.9210,000999,15088,173Feb 10 04:30 PM
MARTIN JOHN CChairman and CEOFeb 02Option Exercise14.50150,0002,175,3754,272,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Option Exercise25.1433,192834,58683,024Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Option Exercise19.0910,000190,850123,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Option Exercise80.652,000161,30036,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Option Exercise26.995,000134,95020,641Feb 04 04:04 PM
MARTIN JOHN CChairman and CEOFeb 02Sale105.43150,00015,815,2494,122,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Sale105.3833,1923,497,66249,832Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Sale105.7312,0001,268,719111,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Sale106.152,000212,31034,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Sale105.675,000528,35815,641Feb 04 04:04 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Option Exercise16.4070,0001,147,650189,302Jan 20 12:46 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Sale98.4770,0006,893,083119,302Jan 20 12:46 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Option Exercise36.721,00036,72035,308Jan 12 03:55 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Sale100.881,000100,88134,308Jan 12 03:55 PM
MARTIN JOHN CChairman and CEOJan 05Sale96.651009,6654,122,987Jan 06 04:20 PM
Whitley Richard JamesDirectorJan 02Option Exercise26.995,000134,95020,641Jan 06 02:12 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.095,00095,425120,694Jan 06 04:20 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise14.50150,0002,175,3754,272,987Jan 06 04:20 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Option Exercise40.561,00040,56035,308Jan 06 04:21 PM
MARTIN JOHN CChairman and CEOJan 02Sale95.11149,90014,257,7224,123,087Jan 06 04:20 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale95.177,000666,192113,694Jan 06 04:20 PM
Whitley Richard JamesDirectorJan 02Sale95.225,000476,10015,641Jan 06 02:12 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Sale95.051,00095,05034,308Jan 06 04:21 PM
Cogan John FrancisDirectorDec 22Option Exercise14.3426,000372,77568,405Dec 24 12:58 PM
Cogan John FrancisDirectorDec 22Sale95.0326,0002,470,75542,405Dec 24 12:58 PM
MILLIGAN JOHN FPresident and COODec 08Option Exercise8.01146,8231,175,3181,120,871Dec 10 05:32 PM
MILLIGAN JOHN FPresident and COODec 08Sale106.26146,82315,601,122974,048Dec 10 05:32 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise8.01140,6331,125,7674,263,620Dec 03 07:13 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise40.562,00081,12036,308Dec 03 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.2931,000752,947149,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Option Exercise26.995,000134,95020,641Dec 03 03:46 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale100.022,000200,03134,308Dec 03 07:14 PM
MARTIN JOHN CChairman and CEODec 01Sale100.72140,63314,164,8294,122,987Dec 03 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale100.7933,0003,325,922116,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Sale100.195,000500,96915,641Dec 03 03:46 PM
Cogan John FrancisDirectorNov 21Option Exercise14.3425,000358,43867,405Nov 25 04:10 PM
Cogan John FrancisDirectorNov 21Sale101.2325,0002,530,77042,405Nov 25 04:10 PM
MILLIGAN JOHN FPresident and COONov 07Option Exercise8.01146,8951,175,8941,120,943Nov 12 12:48 PM
MILLIGAN JOHN FPresident and COONov 07Sale107.37146,89515,772,736974,048Nov 12 12:48 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000055,832Nov 07 01:20 PM
Carter Paul RutherfordEVP Commercial OpsNov 04Option Exercise0.004,800037,044Nov 05 05:37 PM
Whitley Richard JamesDirectorNov 03Option Exercise26.995,000134,95020,641Nov 05 12:23 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Option Exercise40.563,000121,68035,244Nov 05 05:37 PM
MARTIN JOHN CChairman and CEONov 03Option Exercise8.01140,6251,125,7034,570,012Nov 05 02:05 PM
Washington Robin LEVP, CFONov 03Option Exercise25.1433,192834,58683,024Nov 05 08:06 PM
MARTIN JOHN CChairman and CEONov 03Sale110.40140,62515,525,1024,429,387Nov 05 02:05 PM
Whitley Richard JamesDirectorNov 03Sale112.025,000560,09015,641Nov 05 12:23 PM